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The Complement inhibitor K-76 was isolated from the supernatant of the culture broth of the 
fungus Stachybotrys complementi, nov. sp. K-76. The natural product is a sesquiterpenic 
dialdehyde which can be partially oxidized to the monocarboxylic acid derivative (K-76 COOH, 
MX-1), the sodium salt of which is more soluble and less toxic than the natural product. Both, K-
76 and K-76 COOH inhibit Complement activation by the classical and alternative pathways, 
mainly at the C5 level. Reviewed here are the isolation and total syntheses of the natural product 
as well as aspects of its Complement inhibitory activity. Approaches to the synthesis of grisan, 
which bears the BCD skeleton of the natural product, as well as the synthesis of CD-, BCD- and 
ACD-ring structural analogues of K-76, including the use of natural products as starting 
materials, and evaluation of their biological activity as Complement inhibitors, are also 
discussed.  
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1. The Complement system. Structure and activity in health and disease 
 
The Complement system is a phylogenetically conserved element which emerged about 600-700 
million years ago, preceding the emergence of vertebrates and antibody development, and 
evolved as a sophisticated, distinct and important part of the innate immune system, reflecting its 
relevance in protection against non-self. Even sea urchins, which evolved some 700 millon years 
ago, have a functioning Complement system.1 Humans born with highly defective Complement 
systems do not live long before succumbing to infection. The system is composed of about thirty 
plasma and membrane components, factors, regulators and receptors, which are linked in 
biochemical cascades, known as the classical, alternative and lectin pathways.2  
The Complement system is designed to allow unimpeded and rapid activation on a target, 
with strict limitation of such activation in time and space. It plays a critical role in host-defence 
response against infectious pathogens, through its participation in the elimination of potentially 
damaging substances from the body, including self-antigens and apoptotic cells,3 in the 
modulation of the antigen-specific immune response as well as in the initiation of the 
inflammatory response,4 tissue regeneration and interference with tumour growth.5 
Activation of the Complement system most often can take place through the classical, the 
lectin (mannose-binding) or the alternative pathway. Initiation of these cascades is mainly based 
on the detection of surface structures by pattern-recognition proteins. As shown in Figure 1, 
these three proximal pathways converge on Complement component C3. Cleavage of this key 
component yields C3a and C3b, which in turn leads to C5 cleavage with production of C5a and 
C5b; the latter precedes the assembly of the membrane attack complex (C5b-9), capable of 
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causing cell lysis, including those of foreign microorganisms. The peptides C3a and C5a 
(produced and released during Complement activation) are anaphylatoxins, powerful chemo 
attractants for leukocytes, which may cause important tissue damage. 
The three pathways are triggered by different initiators. The classical pathway is activated 
through C1q binding to immune complexes; this induces C1q association with the serine 
proteases C1r and C1s in a large enzymatic complex which is able to cleave C4 and C2, 
producing C4b and C2a, respectively, which assemble to form the classical C3 convertase.  
The alternative pathway is spontaneously activated by hydrolysis of the internal thioester 
bond of C3 generating C3(H2O);6 this slow but permanent activation is markedly enhanced by 
contact with various exposed factors found on foreign surfaces, including microorganisms. The 
C3(H2O) generated by the spontaneous “tick-over” is capable of binding and cleaving factor B 
into Ba and Bb by the protease known as factor D. This process generates C3(H2O)Bb, which is 
able to cleave additional C3 molecules into C3a and C3b. The C3b fragment generated by any of 
the three proximal pathway C3 convertases may also bind factor B, allowing further propagation 
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Figure 1. Schematics of the components, activation pathways and regulation points within the 
Complement system. 
 
Finally, the mannose binding lectin (MBL) pathway is triggered by the binding of MBL to 
repeating carbohydrate residues exposed on target cells. This pathway has been described in 
cases of ischemia and reperfusion of systemic organs, a situation which leads to self-antigens 
exposure, which bind MBL. Then, the mannose-associated serine protease 2 (MASP-2), assists 
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cleavage of C4 and C2, leading to the assembly of a C3 convertase.8 In addition, several other 
proteases such as thrombin, the coagulation cascade serine protease, have been described as able 
to serve as independent or parallel pathway C3 and/or C5 convertases, both in vitro and in vivo.9  
Under normal conditions, this complex mission is accomplished employing different strategies, 
depending upon the nature of the triggering agent: (a) Tagging pathogen cells and promoting 
their phagocytosis; (b) Generating anaphylatoxic responses which lead to local inflammatory 
responses; (c) Promoting membrane attack on pathogenic cells, which results in their lysis; (d) 
Assisting the solubilization and clearance of immune complexes from circulation; (e) Promoting 
an antibody response by helping the immune system to select the appropriate antigens, and (f) 
Helping the body to eliminate self-reactive B cells. Therefore, the Complement system is 
ubiquitous within living species and remains in constant activation. Main Complement effects 
and their corresponding Complement mediators are depicted in Table 1. 
 
Table 1. Main Complement effects and their corresponding Complement mediators 
Effect Complement product(s) involved 
Cell lysis C5b-9 
(MAC, membrane attack complex) 
Inflammatory response  
Chemotaxis and extravasation of white cells (leukocytes) at the 
inflammation site 
C3a, C5a, C5b-7 
Degranulation of eosinophiles C3a, C5a 
Degranulation of mast cells and basophils C3a. C4a, C5a (anaphylatoxins) 
Inhibition of monocyte/macrophage migration and spreading Bb 
Release of neutrophils from bone marrow C3c 
Release of hydrolytic enzymes from neutrophils C5a 
Increased expression of Complement Receptors CR1 and CR3 on 
neutrophils 
C5a 
Opsonization of particulate antigens C3b, C4b, iC3b 
Neutralization of virus C3b, C5b-9 (MAC) 
Solubilization and clearance of immune complexes C3b 
 
The architecture of the Complement system yields an aggressive proteolytic cascade which is 
not able to discriminate between the self and the non-self; consequently, activation of 
Complement entails the potential to destroy harmful as well as harmless cells, including those of 
the host. Therefore, the Complement system is tightly regulated at different levels by a complex 
family of functionally related membrane-bound and soluble proteins. However, deficiencies of 
these regulatory components or excessive activation of Complement in response to certain 
pathological conditions can overwhelm this protective mechanism. Such unbalanced activation 
has been associated with a number of diseases, pathological disorders and situations taking place 
during medical interventions,10 some of which are shown in Table 2.  
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Controlled activation of this system is critical for a proper response. On the contrary, the 
autologous activation of the Complement may lead to disease complications, resulting in 
significant tissue damage with devastating effects. This is often a result from incomplete 
biocompatibility of materials during haemodialysis, use of artificial hearts and the like. 
 
Table 2. Diseases and interventions in which the Complement system is implicated 
Disease/Intervention Process Evidence of Complement involvement 
Immune-mediated 
diseases 
Rheumatoid arthritis Consumption of Complement in acute disease; activation 
products in synovial fluid and on synovial membrane; 
systemic Complement inhibition suppresses disease in animal 




Glomerulonephritis Abundant deposits of Complement activation products, 
including membrane attack complexes, in glomeruli; 
Complement inhibition suppresses disease in models; 
intrarenal administration of Complement regulators suppresses 
disease in models. 
 Multiple sclerosis Activation products found in CSF and around areas of 
demyelination in CNS; Complement inhibition suppresses 
disease in animal models; Complement deficiency suppresses 
disease in rodent models. 
 Myasthenia gravis Abundant activation products at motor end plate during 
attacks; Complement deficiency or depletion abrogates disease 
in rodent models; Complement inhibition (cobra venom factor; 




Alzheimer’s disease Complement activation products in and around plaques in the 







Reperfusion associated with activation in ischemic area; 
abundant deposits of activation products in and around infarct; 
Complement inhibition at time of reperfusion in models 
reduces size of infarct. 
Interventional activation Cardiopulmonary 
bypass 
Hemodialysis 
Complement activation products in plasma; “coating” circuits 
to reduce Complement activation improves outcome. 
 
 Unregulated Complement activation leading to acute inflammation and tissue damage has 
been implicated in the pathology of many disease states.11 Activation of the classical pathway 
has been implicated in humorally mediated graft rejection,12 ischemia–reperfusion injury,13 
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hereditary angioedema,14 vascular leak syndrome,15 and acute respiratory distress syndrome.16 
Complement activation is also an important event during allograft rejection, making the use of 
Complement inhibitors a requirement for long-term graft survival in allotransplantology.17   
These and other often life-threatening effects, including hyperacute rejection of xenografts,18 
necrosis of infarcted heart tissue, brain damage and autoimmune tissue lesions,19 can be 
ameliorated by Complement inhibition.20 Several autoimmune conditions where the Complement 
system is a rational therapeutic target have been listed.21 Surprisingly, only very recently the first 
therapeutic Complement inhibitor has been approved for routine clinical use in specific cases.22 
In addition, the involvement of the Complement system in the early phases of the inflammatory 
response and the wide array of pro-inflammatory consequences of Complement activation,23 
have made this system an attractive target for therapeutic intervention. This has resulted in the 
isolation and synthesis of a host of Complement inhibitors,24 as well as the design of new and 
useful bioactive structures.25 
 
 
2. Complement inhibitors 
 
During the last two decades, the Complement system has been the focus of drug research and 
still remains as a highly active area for drug discovery and lead optimization. Moreover, in 
recent years, the growing understanding of its role in the pathogenesis of various diseases has 
seeded a renaissance of the interest on the development of Complement inhibitors for clinical 
use.26 Different aspects of therapeutic Complement inhibition,27 including the most promising 
Complement inhibitors and their structural requirements for inhibition28 have been the subject of 
several review articles.29  
The search for Complement inhibitors has lead to the discovery and development of several 
new chemical entities, including monoclonal antibodies (eculizumab), recombinant Complement 
regulatory proteins, small peptides and others.30 Examples of these are the small cyclic peptides 
compstatin31 and ‘peptide 2j’, a soluble version of recombinant human CR1 (sCR1) lacking the 
transmembrane and cytoplasmic domains32 and sulphated polymers, like carrageenine, dextran 
sulphate, chondroitin sulphate, polyvinyl sulphate and others such as heparin.33  
During this search, a host of active compounds were found to be useless due to chemical 
instability, low potency, poor selectivity, high toxicity and short half-life. All the currently 
available Complement-inhibiting drugs in clinical use and most of those being clinically tested 
are high molecular weight biotherapeutics.34 Peptidic,35 polysaccharide and protein-based 
Complement inhibitors seem to be highly efficacious and to possess some interesting advantages; 
some of them are highly specific and act at low molar doses. However, they also display some 
serious drawbacks; their production is usually expensive, their formulation is difficult and they 
are potentially immunogenic; in addition, their bioavailability36 and tissue penetration are often 
very limited and some of them cannot be given orally. These inconveniencies constitute serious 
limits to the full potential of these inhibitors.37 
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Many low molecular weight compounds38 and pharmaceutically active ingredients belonging 
to different classes of therapeutic agents, have been found to inhibit Complement; among them 
antiarrhythmics (practolol and procainamide), antibacterials (clofazimine, dapsone and 
isoniazid), antihypertensives (cadralazine, captopril, hydralazine, nifedipine and pindolol), 
antirheumatics (penicillamine), non-steroidal anti-inflammatory agents (acetylsalicylic acid, 
flufenamic acid, indomethacin, niflumic acid, oxyphenbutazone, phenylbutazone and sulindac), 
steroidal anti-inflammatory agents (prednisolone) and tranquilizers (chlorpromazine). This 
prompted Becker as early as in 1972 to note that a list of all compounds capable to inhibit 
Complement would become ‘a catalogue of a chemical supply house’.39  
However, none of them is clinically useful as Complement inhibitor. Therefore, there is an 
urgent need for the development of low molecular weight therapeutically effective Complement 
inhibitors. These therapeutics have been proposed as inexpensive, orally and topically active, 
more tissue-penetrating and patient-preferred alternatives to their labile proteinaceous 
counterparts. Such advantages become more important when the drug must be administered over 
a long period of time, such as during the management of chronic autoimmune disorders.40 
Small-molecule Complement inhibitors have yet to enter the marketplace. Their search and 
design has remained an active area of research during the last 20 years. Compstatin, a synthetic 
13 amino acid cyclic peptide that blocks all three known Complement activation pathways, is 
currently undergoing clinical development for the treatment of age-related macular 
degeneration.41 On the other hand, polysubstituted amidines have been developed to block the 
serine protease activity of C1s. However, therapeutic intervention at more central levels such as 
on the C3 and C5 convertases constitute attractive strategies because this approach can more 
effectively modulate the production of all the critical Complement mediators. Most of the 
regulatory components of the Complement system itself act at this level. Among naturally 
occurring compounds showing Complement inhibitory properties, the biopolymers, including 
polysaccharides, polynucleotides, polypeptides, and proteins appear to be the most actives. Low 
molecular weight compounds, such as flavonoids (rutin and quercetin) and terpenoids, including 
betulinic acid42 and rosmarinic acid,43 also have shown to display anticomplement activity. 
 
2.1. Synthetic non-peptidic low molecular weight compounds as complement inhibitors  
A brief survey of the recent literature indicates that several low molecular weight compounds 
have been shown to possess Complement inhibiting properties. Among the non-peptidic 
chemical entities that have exhibited this activity, the amidino-guanidino type serine protease 
inhibitor FUT-175 (futhan, nafamostat, 1),44 is perhaps the best known (Figure 2).  
Amidine type inhibitors include the Complement inhibitor BCX 1470 2 and compounds 3-5 
carrying a 5-methylthiophene motif. The former was initially discovered in 1997 as a Factor D 
inhibitor with an IC50 of 96 nM, but turned out to be a very potent C1s inhibitor (IC50= 1.6 
nM).45 The latter two are new scaffolds, resulting from a structure-based design of inhibitors of 
factor D, a serine protease of the alternative Complement pathway. These molecules showed a 
highly specific inhibitory profile (IC50= 0.096-0.0016 µM). Compound 5 is considered as one of 
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Figure 2. Representative synthetic inhibitors of the Complement system. 
 
The proteinase inhibitor FOY-305 (camostat, 6) has shown to possess some Complement 
inhibitory activity.47 On the other hand, compounds 7 (SB290157) and its conformationally 
restricted analog 8, which embody the guanidine moiety as part of an arginine residue, act as 
potent C3a receptor antagonists.48 Additionally, carboxylic acids 9, 1049 and 11,50 the disodium 
disuccinate derivative astaxanthin (cardax, 12) and amino acid-related carbamoylphosphinic 
acids such as 13,51 have also shown Complement inhibiting activity (Figure 3).  
On the other hand, Complement inhibitory properties have also been associated to nitrogen 
heterocycles, including pyrazolo[3,4-d]pyridazine 14 (Figure 4),52 derivatives of orlistat 1553 and 
benzylpyridinium salts 16. These novel structures were discovered as a result of structure-
activity relationship studies of several classes of compounds displaying Complement-inhibiting 
activity.54 A good correlation between substituent lipophilicity and electronic properties, 
expressed by Hammett’s constant, was established.55  
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Figure 3. Carboxylic 9-12 and carbamoylphosphinic 13 acid derivatives as Complement 
inhibitors. 
 
Very recently, the group of Bureeva applied this approach in an analogous fashion to 
bisphenol A 17 derivatives (Figure 5), correlating their biological activity with structural 
descriptors as hydrophobicity, polarizability and partial charges.56 Based on their findings, the 
authors concluded that the activity increased with introduction of two anionic groups (sulfate or 
phosphate) and also with bulky hydrophobic substituents, rendering sulfonic acid structure 18 as 
the most active compound of this series. On the other hand, epigallocatechin 1957 is another 





















Figure 4. Complement inhibitors exhibiting various nitrogen-based heterocyclic structures. 
 
Dyestuffs, many of which have been commonly used as medicines during the early 1900s, 
constitute an interesting family of compounds unexpectedly capable to exert anticomplement 
activity. Some examples with proven activity as Complement inhibitors are suramin, trypan blue 
20 and chlorazol fast pink. They share a common structural arrangement of negatively charged 
groups, which may determinate their property to inhibit Complement activation.58 
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Figure 5. Polyphenolics and sulfonic acid derivatives as Complement inhibitors. 
 
2.2. Natural products and semi-synthetic compounds as complement inhibitors 
Natural products remain as the richest source of Complement system inhibitors. Among naturally 
occurring compounds, biopolymers, including polysaccharides (heparin), polynucleotides, 
polypeptides, and proteins appear to be the most active. However, many low molecular weight 
compounds also have shown to display Complement inhibiting properties, among them 
flavonoids such as rutin and quercetin, terpenoids, including betulinic acid (21, Figure 6), 
oleanolic acid 2242 and rosmarinic acid.43  
An elegant and useful approach to discover new lead compounds is based on the 
development of semi-synthetic derivatives of natural products. Usually, the modification of the 
original structure conducts to an improvement on physicochemical and therapeutic profiles 
(solubility, bioavailability, increased bioactivity, minimal toxicity), when compared with its 
natural precursor. Several research groups have been exploiting this approach to discover new 
active steroids and terpenoids derivatives, from natural products with known Complement-
inhibiting properties. Packard and Weiler found a set of steroid sulfates and phosphates capable 
of inhibiting activation of the alternate Complement pathway at relatively high concentrations 
(0.6 mg/mL).59 In a similar approach, Bureeva and co-workers devoted their efforts to find 
selective inhibitors of the reaction of C1q with immunoglobulins and of the classical Complement 
pathway, studying polysulfates derived from triterpenoids and steroids.60 Assefa et al. focused 
their study on the classical Complement pathway-inhibiting properties of betulinic acid (IC50= 
577 µM), oleanolic acid (IC50= 72.3 µM), and some of their negatively charged derivatives, 
finding oleanolic acid ester 23 as the most active compound of this series (IC50= 31.4 µM).42 In 
addition, they also prepared A/B-ring partial analogues of oleanolic acid.61  
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Figure 6. Natural products and derivatives as Complement inhibitors. 
 
On the other hand, ursolic acid was evaluated by Master, showing good profile for the 
inhibition of the classical Complement pathway (IC50= 54.7 µM),62 while Cerqueira and co-
workers found in clionasterol 24 a potent Complement inhibitor (IC50= 4.1 µM).63 However, the 
most prominent naturally-occurring product found to act as an anticomplementary agent is the 
drimanic terpenoid K-76 25, which was extensively studied and employed in numerous 
investigations, as detailed below. 
 
 
3. Isolation of K-76. Simple modifications of the natural product. Activity as 
complement inhibitor 
 
The isolation of K-76 was first reported in 1978 by the group of Inoue, from the culture broth of 
Stachybotrys complementi, nov. sp. K-76, as the result of a massive effort involving the 
screening of over 3000 strains of actinomycetes and fungi. The fungal strain which yielded the 
natural product was isolated from soil obtained from Ishigaki Island, in Okinawa, Japan.64 
K-76 has a drimanic skeleton associated to a polysubstituted benzene ring through a spirofuran 
moiety (Figure 7). Its structure was determined as 25 by various methods including X-ray 
diffraction analysis,65 where the absolute configuration was established by the dibenzoate 
chirality method.66 Silver(I) oxide partial oxidation of the natural product gave K-76 COOH (28, 
also known as MX-1). This compound is able to form a lactol between the adjacent carboxylic 
acid and formyl groups, thus becoming insoluble in water; however, treatment of K-76 COOH 
with sodium hydroxide gives the mono-sodium salt 26, readily soluble in water. Interestingly, 
initial studies attributed structure 27 to K-76 COOH.65,67 
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25, R= H, K-76
26, R= ONa, K-76 CO2Na
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33, R= H, Stypodiol
34, R= OH, Stypotriol
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27 28, K-76 COOH
 
 
Figure 7. Chemical structures of K-76 (25), K-76 COONa (26), K-76 COOH (28) and related 
compounds bearing the grisan (29) skeleton. 
 
The tricyclic skeleton of the BCD ring system of K-76, known as grisan 29 is shared with 
other polycyclic natural products, including the clinically relevant antifungal griseofulvin (30, 
from Penicillium griseo-fulvum Dierckx)68 and filifolinol 31, an antioxidant, antiviral, antifungal 
and antibacterial terpenoid recently isolated from Heliotropium filifolium (Miers) Reiche, H. 
Sclerocarpum Phil. and H. taltalense (Phil.) Johnst (Heliotropiaceae).69  
The tetracyclic ichtiotoxic algal metabolite isochromazonarol 32 from Dictyopteris 
undulata,70 as well as the pentacyclic stypodiol 33, its C14 epimer epistypodiol and stypotriol 
(34), secondary diterpene metabolites excreted by the tropical brown algae Stypopodium zonale 
(Lamouroux) Papenfuss, also share this motif.71,72 These terpenoids display diverse biological 
properties, being particularly toxic and producing strong narcotic and hyperactive effects upon 
the reef-dwelling fish Eupomacentrus leucostictus.  
K-76 demonstrated to be extremely toxic, with LD50= 40 mg/Kg body weight, and when 
injected intravenously to mice, dead took place within 48 h. However, K-76 COONa 26 proved 
to be less toxic, with LD50= 500 mg/Kg in mice. Given daily intravenous or intraperitoneal K-76 
COONa injections of 100 mg/Kg for 3 weeks, rats were able to gain weight normally. Dogs also 
gained weight normally when treated orally with 2 g/Kg/day during 3 weeks.  
It was also observed that K-76 caused hemolysis of sheep and rabbit red blood cells at 
millimolar concentrations; on the other side, K-76 COONa had no hemolytic activity even at 
concentrations of one order of magnitude higher. Neither of both compounds displayed direct 
cytotoxic activity on leukocytes according to the trypan blue test. It was concluded that the 
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natural product and K-76 COOH have a unique Complement inhibitory activity, due to their 
ability to inhibit the generation of anaphylatoxin C5a (IC50= 3 mM) a peptide released upon 
Complement activation. Under these conditions, little inhibition of C3a production was observed. 
In laboratory experiments, K-76 COOH has demonstrated to play an important role in 
diminishing gastric mucosal damage induced by ischemia-reperfusion in rats,73 and on the 
survival of discordant cardiac xenografts from guinea pig to rat and from pig to human.74  
In addition, the natural product derivative 28 has been employed, among other situations, for 
the development of a new treatment for the ulcerative colitis,75 for blocking human lymphocyte 
cell-mediated cytotoxicity and antibody-dependent natural cytotoxicity,76 and as a 
noncompetitive inhibitor of the enzyme inositol monophosphatase.77 Furthermore, K-76 COOH 
protected MDP-primed C3H/HeJ mice from mortality in the anaphylactoid reaction induced by 
Prevotella intermedia and Salmonella typhimurium lipopolysaccharides, respectively. It also 
inhibited platelet degradation, but not their accumulation induced by P. intermedia,78 and 
protected BALB/c mice from mortality in the anaphylactoid reaction.79 
 
3.1. Stachybotrys sp. derived natural products structurally related to K-76  
The unique skeleton of K-76 is also shared with other novel bioactive compounds which have 
been isolated from different strains of Stachybotrys (and the closely related Memnoniella) 
species (Figure 8). These include, among others, stachybotrylactam (35, from Stachybotrys 
chartarum or S. atra), stachybotrin A 36 and stachybotrin 37 (from Stachybotrys alternans), 
stachybotrilactone (38, stachybotrolide) and congeners 39-40,80 and the dimeric stachybocins 41-
43, isolated from Stachybotrys sp. M6222, which are active as antagonists of endothelin and 
inhibit HIV-1 protease.81  
Other members of this family are the inhibitor of inositol monophosphatase L-671,776 (44 
from S. chartarum and Memnoniella echinata),82 the antiviral and enzyme inhibitor 
stachybotrydial (45, from Stachybotrys sp. F-1839 and S. cylindrospora),83 as well as the 
pancreatic cholesterol esterase inhibitors F-1839-A, F-1839-B, F-1839-E and F-1839-F (46-49, 
respectively, from Stachybotrys sp. F-1839)84 and the structurally simpler triprenylphenols 50 
and 51 (from Stachybotrys chartarum), which act as tyrosine kinase receptor inhibitors.85  
The staplabins (formerly included among the stachybotrins) such as SMTP 0 (47, also known 
as stachybotrin B, from Stachybotrys microspora),86 and the related 53 and 54, also display 
simplified versions of the basic skeleton; on the other hand, the stachyflins (55 and 56, from 
Stachybotrys sp. RF-7260), the first of which is a potent and novel anti-influenza A virus agent, 
are examples of structurally modified compounds, which include skeletal rearrangements.87  
 
 
4. Chemical syntheses of K-76 
 
4.1. The K-76 synthesis of Corey and Das 
To date, there are three reported total syntheses of K-76. The first synthesis of the natural 
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product and derivatives was carried out by Corey and Das,88 who took advantage of the ready 





















35, X= N, R1= R2= H, Stachybotrylactam
36, X= N, R1= Me, R2= (CH2)2OH, Stachybotrin A
37, X= N, R1= H, R2= (CH2)2OH, Stachybotrin
38, X= O, R1= H, Stachybotrilactone
39, X= N, R1= H, R2= CH(CO2H)(CH2)2CO2H
40, X= N, R1= H, R2= CH(CO2H)CH(OH)Me
41, R1= R2= H, Stachybocin A
42, R1= OH, R2= H, Stachybocin B
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46, R1=R2= H, F-1839-A
47, R1= OMe, R2= H, F-1839-B
48, R1= H, R2= (CH2)2OH, F-1839-E
49, R1= H, R2= (CH2)3CO2H, F-1839-F
50, R1= H, R2= (CH2)3CHMe2
51, R1= H, R2= CH(CO2H)CHMe2
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Figure 8. Stachybotrys-derived natural products related to K-76. 
 
Enolization of 58 followed by treatment with triflic anhydride afforded enol triflate 59 
(Scheme 1), which was reacted with LiMe2Cu, yielding the β-methyl α,β-unsaturated ester 60. 
LiAlH4 reduction of the ester and conversion of the resulting alcohol to the allylic bromide 61 
through the related mesylate, was followed by coupling with 62a, the lithium derivative of acetal 
62, to give 75% of the tricyclic acetal 63.  
Regional Issue "Organic Chemistry in Argentina"  ARKIVOC 2011 (vii) 49-102 




































































28, R1= CO2H, R2= CHO



















Scheme 1. Reagents and conditions: a) 1. NaH, MeC(O)CH2CO2Et, nBuLi, Et2O, 0ºC, 1h (95%); 
2. NaH, ClP(O)(OEt)2, Et2O, rt, 2h; 3. Hg(TFA)2, MeNO2, -20ºC 0ºC; NaCl (60%); 4. KI3, 
Dioxane; 5. LiCl, DMF, rt, 48h (70% overall); b) 1. NaH; 2. Tf2O (90%); c) LiMe2Cu, Et2O, -
78ºC to -30ºC, 2h (90%); d) 1. LiAlH4, Et2O, 4h; 2. MsCl, Et3N, CH2Cl2, -50ºC, 10 min.; 3. 
LiBr, THF, -50ºC 0ºC, 1h; e) 62, nBuLi, THF-TMEDA, HMPA, -78ºC 0ºC, 1h (75%); f) 1N 
HCl-THF (1:3), rt, 1h (93%); g) 2N HCl, HOCH2CH2OH-THF (2:1:4), rt, 48h (50-70%); h) 1. 
TsOH, MeOH, rt, 1h (97%); 2. Bu4NI3, CH2Cl2, rt, 10 min; 3. ClCH2OMe, 0ºC, 15 min (85%); i) 
1. CuCN, HMPA, 85ºC, 24h (90%); 2. KOH, tBuOH, reflux, 48h (92%); j) OsO4, Py, rt, 16h 
(80%, 1:1 mixture of 2α,3α and 2β,3β diols); k) 1. 1N HCl, THF, rt, 1h (99%); 2. MeOH, TsOH, 
rt, 1h; 3. Me2CO, 2,2-DMP, TsOH, rt, 1h (90%); l) N2O4, NaOAc, CCl4, 0ºC, 30 min.; m) 
DIBAL-H, PhMe, -78ºC, 10 min; 2. 1N HCl-THF (1:5), rt, 30 min; n) 6N HCl-THF (1:1), rt, 4h 
(87%); o) Ag2O, 1N NaOH, rt, 30 min. 
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The symmetric acetal 62 was prepared in 63% overall yield from the commercially available 
methyl 3,5-dihydroxybenzoate by a four-step sequence which included transformation to the 
bis(methoxymethyl) ether (MOM) derivative, followed by reduction of the ester to the primary 
alcohol with lithium aluminium hydride, oxidation of the latter to the aldehyde and final 
acetalization with MeOH under TsOH catalysis. 
Mild acid hydrolysis of 63 gave aldehyde 64, which upon submission for two days to 2N HCl 
in a THF-ethylene glycol mixture, resulted in MOM hydrolysis and cyclization yielding phenol 
65. The trans-diaxial addition to the double bond which took place established the desired 
geometry of both, the dihydrofuran ring and the neighbouring methyl group. The authors 
discovered that the use of acetal 62b instead of its congener 62a furnished poor yields (26%) of 
cyclized material. 
Reacetalization of 65 with TsOH in MeOH was followed by iodination with nBu4NI to the 
iodide and further transformation in situ to the corresponding methoxymethyl ether 66. 
Replacement of the iodine with a cyano moiety and subsequent basic hydrolysis of the resulting 
nitrile furnished the amide 67 in over 80% yield from the iodide 66. 
Next, installation of the cis-diol moiety was taken care of. Unfortunately, dihydroxylation of 
67 yielded a 1:1 mixture of both possible cis-diols. However, the synthesis went ahead and the 
cis-diol 68 was transformed into methoxy lactam 69 by acid hydrolysis of the acetal moiety 
followed by lactamization and acetalization of the resulting lactam-hemiacetal with TsOH in 
MeOH and final acetalization of the diol moiety with acetone, 2,2-dimethoxypropane and tosic 
acid. Treatment of 69 with dinitrogen tetraoxide gave the diastereomeric methoxy lactones 70, 
while reduction of the lactone carbonyl of 70 with DIBAL followed by acid deketalization 
furnished dialdehyde 71. Hydrolysis of the MOM ether moiety finally yielded K-76. Oxidation 
of synthetic K-76 with silver(I) oxide in 1N NaOH yielded K-76 COOH, which the authors 
demonstrated to possess structure 28, contrary to the previously assigned isomeric structure 27. 
Interestingly, the poor yields and stereochemical problems associated to the cis-
dihydroxylation of the 2,3-double bond of the A-ring, initially found by Corey and Das would 
plague the other syntheses of the natural product, becoming more than once their Achilles’ heel. 
 
4.2. The K-76 synthesis of McMurry and Erion 
Three years later, McMurry and Erion also reported a total synthesis of K-76.90 In their first 
attempt involving the coupling of allyl bromide 61 with acetal 82, the strategy exhibited several 
broad analogies with the original route devised by Corey and Das. 
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Scheme 2. Reagents and conditions: a) 1. Hg(OTf)2, MeNO2; 2. NaCl (71%); b) 1. (PhSe)2, 
PhH, hν (sunlamp); c) NaIO4, THF-H2O, 0ºC, 12h (83%); d) 1. KH, DME, 60ºC, 30 min; 2. 
tBuOH, 5 min (90%); e) LiAIH4, Et2O, 0ºC rt, 15 h (74%); f) PBr3, Et2O, 0ºC, 10 min (99%). 
 
For the synthesis of 61, ethyl farnesate (72) was cyclized with mercury(II) triflate, yielding 
the chloromercurial bicyclic ester 73, which was transformed into selenium derivative 74 with 
(PhSe)2 under (sun)light promotion (Scheme 2). Sodium periodate-mediated oxidation of the 
phenyl selenide followed by elimination of the resulting selenoxide, efficiently (82% yield) 
installed the 2,3-double bond (75), while addition of tert-butanol to the reaction medium resulted 
in the potassium tert-butoxide mediated isomerization of the double bond of ring B to furnish 
α,β-unsaturated ester 76, analogous to one of Corey’s intermediates. Reduction of the ester to the 
corresponding allylic alcohol 77 and treatment of the latter with PBr3 yielded the required allyl 
bromide intermediate 61 (previously prepared by Corey and Das) in 44% overall yield. 
On the other hand, bis-TBDMS ether 82 was synthesized from the methyl enol-ether of 1,3-
cyclohexanedione (78) employing a multi-step sequence (Scheme 3). First, the enone was 
converted into a 1,3-diene by a KH-mediated enolization, following by TMSCl trapping of the 
enolate; subsequent Diels-Alder reaction with dimehyl acetylene dicarboxylate gave an 
intermediate which upon heating at 120ºC followed by exposure to silica gel during 
chromatography underwent a retro-Diels-Alder reaction with loss of ethylene, and further acid-
promoted desilylation, furnishing phenolic derivative 79 in 71% overall yield. Protection of the 
phenol as the tetrahydropyranyl ether (80), followed by reduction of both ester groups and 


















Scheme 3. Reagents and conditions: a) 1. KH, TMSCl, THF; 2. DMAD; 3. ∆ (120ºC); 4. SiO2 
(chromatography) (71%); b) DHP, TsOH, CH2Cl2 (82%); c) LiAIH4, Et2O-PhH (99%); d) 
TBDMSCl, Imidazole, rt, 24h (93%). 
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Fragment coupling was performed by nBuLi-TMEDA lithiation of 82, followed by alkylation 
with the allyl bromide 61. Next, TBAF-mediated removal of the silicon-based protecting groups 
and Swern oxidation of the benzylic alcohols yielded the dialdehyde 83, which upon acid 
hydrolysis furnished the free phenol 84 ready for cyclization (Scheme 4). This was performed by 
treatment of 84 with the strong acid ion-exchange resin Amberlyst-15, which afforded 56% of 
the desired tetracyclic product (85). However, at this point the synthesis met a serious obstacle. 
Attempts to dihydroxylate 85 to 86 met with failure, as other experiments intending to introduce 
the diol moiety at early stages of the sequence. It was concluded that severe 1,3-diaxial 
interactions between the axial methyl groups supported on the cyclohexene ring A (87) were 
responsible of holding the A-ring in a boat-like conformation during the reaction with OsO4, 
hiding the α-face from attack and hindering the reaction. 
An alternative strategy was then devised, based on the information given by molecular 
models, which suggested that masking the gem-dimethyl moiety as a spiro-fused cyclopropane 
ring would allow proper changes in the geometry of ring A, which would facilitate the 
dihydroxylation. The strategy, which hinged upon the use of an alkylidenecyclopropane 
derivative as initiator for an electrophile-induced polyene cyclization, also took into account that 
hydrogenolytic ring opening of the cyclopropane ring could easily generate the required gem-






































Scheme 4. Reagents and conditions: a) nBuLi, TMEDA, hexane, 0ºC (65%); b) 1. TBAF, THF, 
rt, 30 min (100%); 2. (COCl)2, DMSO, Et3N, CH2Cl2 (Swern [O]); 3. AcOH, THF-H2O, rt, 13h 
(86%, overall); c) Amberlyst-15; CH2Cl2, 8.5h (56%). 
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Therefore, the key allylic bromide intermediate 101 was prepared from aldehyde 88, in turn 
easily available in 61% yield as a product of the selective ozonolysis of geranyl acetate (Scheme 
5). Wittig reaction of 88 with cyclopropylidene triphenylphosphorane furnished the 
alkylidenecyclopropane derivative 89, which was transformed into the related allylic bromide 91 
through basic hydrolysis of the acetate moiety and treatment of the resulting alcohol (90) with 
PBr3. Next, alkylation of bromide 91 with the dianion of methyl acetoacetate furnished β-
ketoester 92, which was converted into cyclization substrates 93 and 94 by trapping the 
corresponding enolates with ClP(O)(OEt)2 and TBDMSCl, respectively. 
However, treatment of alkylidenecyclopropane 93 with mercury(II) trifluoroacetate, followed 
by hydrolysis and anion exchange with NaCl, gave poor yields of the sought tricyclic product. 
On the contrary, reaction of the more nucleophilic enol silyl ether 94 under the same conditions, 
furnished an organomercurial polysubstituted decaline in 57% isolated yield.  
This was followed by protection of the ketone as ethylene ketal with ethyleneglycol bis-TBDMS 
ether and TMSOTf in 85% yield, conversion of the organomercurial moiety into the related 
phenylselenide under sunlamp irradiation and a final hydrogen peroxide-mediated oxidation-

































98, R1= CO2Me, R2= OPO(OEt)2
99, R1= CO2Me, R2= Me
100, R1= CH2OH, R2= Me







Scheme 5. Reagents and conditions: a) NaH, cyclopropyl-PPh3+Br-, DME, 60ºC, 12h; b) K2CO3, 
MeOH, rt, 1h (66% from 88); c) PBr3, Hexane, 0ºC, 20 min (100%); d) 1. NaH, 
MeC(O)CH2CO2Me, THF; 2. nBuLi (75%); e) ClP(O)(OEt)2 (93) or Imidazole, TBDMSCl, 
DMF, rt, 24h (94, 90%); f) 1. Hg(O2CCF3)2, MeNO2, -5ºC, NaCl (57%); 2. 
TBDMSOCH2CH2OTBDMS, TMSOTf, CH2Cl2, 0ºC, 7h (85%); 3. (PhSe)2, PhH, hν (sunlamp), 
1.5h (93%); 4. H2O2, THF, 0ºC rt, 15h (91% overall); g) 1. OsO4, NMO, tBuOH-H2O, rt, 12h 
(2α,3α/2β,3β= 12:1, 88%); 2. H2 (520 psi), PtO2, AcOH, rt, 48h (99%); h) 1. 2N HCl-THF (1:1), 
rt, 26h; 2. Me2CO, Aberlyst, rt, 2h (85%); i) NaH, DME, ClP(O)(OEt)2; j) MeLi, CuI, Et2O, -
78ºC -23ºC, 2.5h; k) LiAlH4, Et2O, 0ºC, 4h (71% overall); l) 1. MsCl, Et3N, CH2Cl2, -50ºC, 45 
min; 2. LiBr, THF, -20ºC, 1h (> 90%).  
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The next pair of critical steps included the osmium tetraoxide-mediated dihydroxylation of 
95, which the authors were able to carry out in a catalytic fashion, yielding the desired α,α-diol 
as the main diastereomer product, and the hydrogenolytic cleavage of the cyclopropyl moiety, 
which was accomplished with Adams catalyst in AcOH, to provide 96 in quantitative yield.  
Acid hydrolysis of the ketal moiety of 96 and protection of the diol as the acetonide under 
Amberlyst-15 catalysis furnished 85% of β-ketoester 97, which was next subjected to 
transformation into the β-methyl α,β-unsaturated ester 99 via the enol-phosphate intermediate 
98. In turn, this was reduced to the related alcohol (100) and converted to the required allyl 
























Scheme 6. Reagents and conditions: a) MOMCl, K2CO3, Me2CO, 0ºC rt, 15h (99%); b) 
LiAlH4, Et2O, 0ºC rt, 2h; 2. (COCl)2, DMSO, Et3N, CH2Cl2 (Swern [O]) (89%); c) TsOH, 
MeOH, CH2Cl2, 0ºC, 20 min (91%). 
 
A new aromatic coupling component (104) was also prepared from the previously 
synthesized 79. As shown in Scheme 6, this was accomplished through protection of the phenol 
moiety as MOM-ether, followed by reduction of the esters to the corresponding alcohols with 
LiAlH4, partial reoxidation of the diol under Swern conditions to phthaldehyde derivative 103 
and final bis-acetalization with TsOH in MeOH. 
Coupling of acetal 104 with bromide 101 took place to furnish intermediate 105. The 
coupling strategy employed the organocopper derivative of 104, because the original aryl-lithium 
mediated coupling strategy proved unsuccessful (Scheme 7). Aqueous acid hydrolysis 
simultaneously effected acetonide, acetal and MOM-ether cleavage, furnishing advanced 
intermediate 106 in 59% overall yield and setting the stage for culmination of the sequence. 
However, application of the originally developed cyclization conditions met with failure, 
being 106 either reluctant to cyclize under other acidic conditions, furnishing six-membered 
ether derivatives or resulting in complete destruction of the starting phenol. On comparison with 
the cyclization of 84, this reluctance was attributed to the presence of the 2α,3α-diol moiety. It 
was conjectured that the basicity of these hydroxyl groups could hinder protonation of the B-ring 
double bond, turning compound 106 more labile to acid-catalyzed decomposition. In order to 
mitigate this unwanted effect, diol 106 was protected by treatment with phenylboronic acid, 
quantitatively giving phenyl boronate 107.  
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Scheme 7. Reagents and conditions: a) tBuLi, TMEDA, THF, CuCN, -78ºC -15ºC, 8h; b) 2N 
HCl, 2-PrOH-THF (10:10:1), 15h, rt (59% overall); c) PhB(OH)2, MgSO4, PhH, rt, 15h (100%); 
d) Amberlyst-15, PhH, rt, 37h (45%); e) tBuSLi, HMPA, rt, 7h (75%). 
 
The protective group was chosen on the assumption that overlapping of the oxygen lone-pair 
of electrons with the vacant boron orbital should be effective in deactivating the oxygens toward 
protonation. This effect was observed as a large downfield shift for the C2 and C3 protons of 
boronate 107 relative to those of diol 106, presumably due to the expected lower electron density 
on the C2 and C3 oxygens. 
 As expected, 107 was smoothly cyclized in the presence of excess Amberlyst-15 in benzene 
to furnish O-methyl K-76 (87), together with pyranic diastereomeric derivatives 108 in a 1.7:1 
ratio and 72% overall yield. Final cleavage of the methyl ether was accomplished with in situ 
generated lithium tert-butyl mercaptide (tBuSH and nBuLi), providing K-76 (25) in 75% yield. 
Interestingly, the kampanols A-C (109a-c) are drimanic benzopyran derivatives (Figure 9) 
tightly resembling the structure of 108; they have been recently isolated from Stachybotrys 
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kampalensis Hansf (MF 6199, ATCC 74357),91 obtained from leaf litter, collected at the Palo 








109a, R1= O; R2= H, Kampanol A



















109d, AB= CH2-CH2, R= H, Thailandolide A
109e, AB= CH=CH, R= OAc,Thailandolide B
 
Figure 9. Examples of naturally occurring drimanic derivatives carrying benzopyran skeletons. 
 
 These compounds have demonstrated to possess interesting inhibitory activity on the 
farnesyl-protein transferase (IC50= 7-13 µM), having the potential of being novel anticancer 
agents for tumours in which the ras oncogene is found mutated and contributes to cell 
transformation.92 They also resemble the thailandolides A and B (109d,e), recently reported 
merodrimanes isolated from the previously undescribed fungus Talaromyces thailandiasis.93 
 
4.3. The K-76 synthesis of Mori and Komatsu 
Taking advantage of McMurry’s synthesis, which employed α,β-unsaturated ester 99 as key 
intermediate, Mori94 expected to accomplish an enantioselective synthesis of K-76 by preparing 
this intermediate in optically active form, from (S)-β-hydroxy ketone 111. This starting material 
is easily available through a biotransformation which involves the baker’s yeast-assisted 
reductive desymmetrization of 1,3-diketone 110.95  
Initially, 111 was converted into bicyclic ketol 112 in seven steps (Scheme 8).96 Next, 
dehydration of the alcohol was performed in 89% yield via the corresponding triflate, and the 
resulting olefin was cis-dihydroxylated with stoichiometric amounts of OsO4, yielding a mixture 
of cis-diols from which the desired 113 could be isolated in 36% yield. This was uneventfully 
transformed into acetonide 114, which after some experimentation was converted to the α,β-
unsaturated ketone 115 in 37% overall yield by the Reich sequence, involving α-selenenylation 
with LDA and BnSeCl, followed by ozonation and elimination of the resulting selenoxide.97 
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Scheme 8. Reagents and conditions: a) Baker’s yeast, sucrose, water, 30ºC, 48h (79%, 99% ee); 
b) 1. DHP, TsOH, CH2Cl2 (100%); 2. LDA, H2C=CHCH2CH2I, THF-HMPA (92%); 3. LDA, 
MeI, THF-HMPA (93%); 4. PdCl2, CuCl, O2, DMF-H2O (77%); 5. Pyrrolidine, PhH (89%); 6. 
MeOH, TsOH (84%); 7. H2, Pd/C, MeOH (96%); c) 1. TfCl, DMAP, CH2Cl2, -10ºC 0ºC, 4h 
(89%); 2. OsO4, Pyridine, THF, rt, 88h (36%); d) Me2CO, TsOH, rt, 5h (98%); e) 1. BnSeCl; 2. 
O3 (37%); f) 1. (H2C=CH)2CuLi; 2. TMSCl; 3. LiNH2, MeI (116, 16%).  
 
The required conjugate addition-alkylation stage could not be performed as a one-pot 
process. Therefore, the enolate resulting from lithium divinyl cuprate was trapped as a TMS enol 
ether, which was subsequently treated with LiNH2 to effect lithiation, prior to alkylation with 
methyl iodide. However, the attained yields of 116 were 16% at best, being 117 the major 
product. Therefore, the sequence was abandoned in favour of an alternative strategy, designed to 
overcome the difficulties found during the introduction of the C8 and C9 substituents.  
Thus, these functionalities were built at early stages of the synthesis, as shown in Scheme 9. 
For that purpose, 111 was protected as the TBDMS ether and this was subjected to addition of 
acetylene, followed by CuSO4-mediated dehydration and partial hydrogenation with Pd-CaCO3 
in the presence of quinoline, which provided diene 119 in 50% overall yield.98 In turn, this was 
heated with dimethyl acetylene dicarboxylate to furnish, after deprotection, 1,4-diene 121 (29%) 
along with its C10 diastereomer 120 (32%) and 15% of the bicycle carrying fully aromatized 
ring B, as result of a Diels-Alder reaction. Chromatographic separation of the diastereomers 
afforded key intermediates for the synthesis of the natural (-)-K-76 and the methyl ether of the 
unnatural enantiomer, O-methyl (+)-K-76 (128c). 
Partial hydrogenation of the non-conjugated double bond of diester 120 furnished 80% of 
122, which was quantitatively protected as the TBDMS ether 123. Selective reduction of the C8-
supported methyl ester with DIBAL-H gave 63% of primary allylic alcohol 124, which was 
hydrogenolytically deoxygenated (93%),99 and subsequently deprotected with HF in MeCN to 
yield 87% of 125.  
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Scheme 9. Reagents and conditions: a) TBDMSCl, Imidazole, DMF, 40ºC, 18h (81%) ; b) 1. 
LDA, THF-HMPA, MeI, 78ºC 0ºC, 30 min (72%); 2. NaC≡CH, Et2O-NH3(liq.) (99%); 3. 
CuSO4, Xylene, reflux (51%); 4. H2, Pd/CaCO3, Quinoline (100%); c) 1. MeO2C-C≡C-CO2Me, 
100-105ºC (sealed tube), 32h; 2. HF, MeCN, rt, 3h (120, 32%; 121, 36%); d) H2, 10% Pd/C, 
MeOH (80%); e) TBDMSCl, Imidazole, DMF, rt, 20h (100%); f) DIBAL-H, PhMe, -65ºC, 30 
min (63%); g) 1. H2, 10% Pd/C, EtOAc (93%); 2. 46% HF, MeCN (1:60), rt, 2h (87%); h) 1. 
TsCl, Pyridine, rt, 41h (97%); 2. DBU, Bu4NBr, DMF, 90ºC, 44h (77%); i) OsO4, Pyridine-THF 
(126a, 21%; 126b, 46%).  
 
Generation of the required double bond in ring A and conjugation of the double bond of ring 
B were next undertaken. This was accomplished by tosylation of 125, followed by treatment of 
the resulting tosylate with the DBU-tetrabutylammonium bromide reagent in DMF,100 which 
simultaneously effected elimination of TsOH and double bond isomerization, furnishing 5S-60 
(the racemic ethyl ester of which was previously prepared by McMurry and Erion), in 77% 
overall yield. Osmium tetraoxide-mediated dihydroxylation of 5S-60 finally gave a 1:2 mixture 
of both possible cis-diols 126a and 126b, in 67% overall yield.  
The total synthesis of (-)-K-76 was then completed, employing McMurry and Erion’s protocols 
and starting from 5S-99, the optically active acetonide of 126a. The overall yield of the synthesis 
was 0.021%, in 25 steps from S-111. The synthetic compound was compared with the natural 
product, exhibiting similar specific optical rotation data and no melting point depression when 
mixed with the natural K-76. 
 
4.4. Enantioselective syntheses of diastereomeric compounds closely related to K-76 
Mori and Komatsu also synthesized 128a employing the 2β,3β-diol 126b, resulting from the β-
dihydroxylation of 5S-60, through the intermediacy of acetonide 127a, as shown in Scheme 10. 
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Similarly, using 130 as starting material and resorting to a very similar strategy, allyl bromides 
127b and 127c were prepared. These were then employed for the syntheses of 128b and 128c 
[(+)-O-methyl K-76]. Interestingly, cyclization leading to the β-diol analogue of K-76 128a, 
which was accomplished in 16% yield, furnished the related benzopyran isomer 129 as the major 













































































5. Syntheses of Grisan, the tricycle embodying the BCD ring system of K-76 
 
5.1. Synthesis of grisan by Antus and co-workers 
Grisan (29) was the name originally given by the group of Grove101 to the spiro[benzofuran-
2(3H)-l’-cyclohexane] skeleton characteristic of griseofulvin (30). The synthesis of griseofulvin 
has received much attention during the 1960’s and the 1970’s,102 but its basic skeleton (29) was 
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first synthesized by chance, by Antus and co-workers in 1986 during their attempt of preparing 
hexahydroxanthenes (Scheme 11).103 
These authors condensed cyclohexanone (131) with salicylaldehyde benzyl ether (132) under 
piperidine catalysis to obtain 51% of α,β-unsaturated ketone 133, which was reduced to the 
allylic alcohol 134 with NaBH4 or DIBAL-H (90-92% yield) and then catalytically hydrogenated 
with Pd/C to yield a mixture of cis and trans alcohols 135 and 136 in 52% overall yield. 
Treatment of the cis alcohol with BF3.Et2O or TsOH gave 80% of the spiro-tricyclic compound 
29 through the intermediacy of 140, while the trans alcohol remained reluctant to cyclize under 
BF3.Et2O promotion, yielding a 6:1 mixture of cis and trans hexahydroxanthenes 138 and 139 in 





































Scheme 11. Reagents and conditions: a) EtOH, Piperidine, reflux, 48h (51%); b) NaBH4, EtOH, 
15 min (92%) or DIBAL-H, PhMe, -65ºC, 30 min (90%); c) H2, Pd/C, MeOH (135, 40%; 136, 
12%); d) TsOH, PhH, reflux, 160h (139, 46%; 138, 8%); e) BF3.Et2O, CH2Cl2, rt, 100h (80%). 
 
Cyclization of deuterium labelled precursors revealed that formation of the spiro-derivative 
29 involved a 1,2-hydrogen shift. It was concluded that during the formal elimination of water 
the oxygen and the neighbouring tertiary hydrogen atom can adopt anti-periplanar positions only 
in the case of the cis diastereomer 135. This hydrogen atom can thus undergo the observed 
hydride shift upon concomitant attack of the phenolic OH at the tertiary centre. However, the 
diastereomer 136 is unable to adopt this conformation, necessary for such a hydride migration; 
therefore, only xanthene derivatives 138 and 139 result from the acid-catalyzed cyclization. The 
main product (139) is formed under SN2-conditions by inversion leading to the 
thermodynamically less stable cis-compound. However, since the SNl-type reaction is a 
competitive path, minor amounts of the trans-diastereomer 138 are also formed. 
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5.2. Synthesis of grisan by Kaufman and Sindelar 
Shortly after Antus findings, Kaufman and Sindelar reported a short and more efficient synthesis 
of grisan.104a In their three-step sequence, the easily available MOM-ether derivative 141 was 
ortho-metallated104b,c with nBuLi-TMEDA in THF and subjected to a copper(I)-assisted coupling 
with l-chloromethyl cyclohexene (142), furnishing 95% of 143 (Scheme 12). Careful acid 
hydrolysis of the acetalic protecting group with 3N HCl cleanly afforded cyclohexenyl phenol 
144 in 94% yield, which furnished 94% of grisan (29) upon treatment with an excess of 











Scheme 12. Reagents and conditions: a) 1. nBuLi-TMEDA, THF, 0ºC RT, 1.75h; 2. CuI, -
45ºC, 1h; 3. 1-chloromethyl-cyclohexene (142), overnight (95%); b) 3N HCl, 2-PrOH, H2O, rt, 
overnight (94%); c) Amberlist-15, CH2Cl2, rt, overnight (94%). 
 
5.3. Synthesis of grisan by Snider and co-workers 
Following Watt’s initial report on the α’-acetoxylation of 2-cyclohexenone (145) with P2O5-
dried Mn(OAc)3 in refluxing benzene,106 the group of Snider found that intramolecular trapping 
of the α’-keto radicals obtained from cyclohexenones by suitably located olefins takes place 













146 147 148 149
- H+
+ Mn(OAc)3
- H+ + Mn(OAc)3




Scheme 13. Reagents and conditions: a) Mn(OAc)3 (≥ 4 equiv.), PhH, ≥ 80ºC, 3 days. 
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 When studying the intermolecular version of this transformation, they found that the 
Mn(OAc)3-mediated oxidative addition of 2-cyclohexenones with methylenecyclohexane in 
refluxing benzene gave 25-42% of dihydrobenzofuran derivatives and up to 18% of 6-(1-
cyclohexenylmethyl)-2-cyclohexenones. In this way, grisan (29) was made available in 42% 
overall yield, in a one pot process (Scheme 13), together with 18% of cyclohexenylmethyl 
derivative 149. In a similar fashion, even complex compounds such as 154 (from α-tetralone) 
bearing the same motif, where made easily available in reasonable yields.108 
Mechanistically, oxidation of the cyclohexenone 145 forms α’-keto radical 146, the addition 
of which to the olefin furnishes radical 147; being tertiary, 147 is readily oxidized by Mn(OAc)3 
to cation 148,109 which may lose a proton to give the 2-alkenyl-2-cyclohexenone side product 
149. However, cyclization of 148 to the bicyclic cation 150 is also a viable alternative; in such 
case, loss of a proton will give tetrahydrobenzofuran 151 or a double bond positional isomer. 
Taking into account that electron-rich double bonds are easily oxidized to radical cations by 
Mn(OAc)3,110 dienyl ether 151 may become oxidized to grisan through the intermediacy of 
cation radical 152. In fact, after losing a proton, 152 would yield radical 153, the final oxidation 
of which would give a cation, that after losing a proton should afford grisan (29).  
 
 
6. Synthesis of K-76 analogues and related compounds for biological testing 
 
6.1. Synthesis and evaluation of CD-ring analogues 
In search for the pharmacophore of K-76, and after some in vitro results suggesting that the 
lipophilic moiety of K-76 analogues may be causing unwanted lytic activity, Srivastava and co-
workers prepared a series of CD-ring analogues of K-76 (Scheme 14), featuring different 
substituents on C6 (formyl, carboxylic acid, tetrazole) and C4 (OH, OMe, OPh).111  
In their synthesis, bis-MOM derivative 155 was subjected to lithiation and coupled with 
methallyl chloride employing organocopper chemistry (156). Fluoro-desilylation of the silyl 
ether moiety was followed by PCC-mediated partial oxidation of the benzylic alcohol (157) to 
the aldehyde (158), which in turn was deprotected and cyclized under acidic conditions, 
furnishing bicycle 159 in 65% overall yield. Methylation and phenylation of the free phenol 
group yielded congeners 160 and 161, which together with 159 were subjected to a silver(I)-
mediated oxidation to the corresponding carboxylic acids (162-164) in good yields.  
The protected intermediate aldehydes 160 and 161 were also transformed into the 
corresponding tetrazoles 167 and 168, bio-isosteric with the corresponding carboxylic acids 163 
and 164,112 in three step processes which involved formation of the oximes by treatment with 
hydroxylamine, oxime dehydration to form the corresponding benzonitriles 165 and 166 in 85 
and 91% yield, respectively, and final treatment of the latter with NaN3 and NH4Cl in refluxing 
DMF to which LiCl has been added. 
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Scheme 14. Reagents and conditions: a) nBuLi, TMEDA, CuI, H2C=C(CH3)CH2Cl (83%); b) 
TBAF, THF; c) PCC, CH2C12 (89%, overall) d) 3N HCI, 2-PrOH, rt, 8h (92%); e) CH3I, Ag2O, 
CHCl3 (68%); f) Ph3Bi(OAc)2, Cuº, CH2C12 (61%); g) AgNO3, KOH, EtOH, H2O (162, 64%); 
h) 1. NH2OH.HCl, NaOAc, MeOH; 2. SOC12, PhH, reflux (165, 85%; 166, 91%); i) NaN3, 
NH4Cl, LiCl, DMF, reflux, 52h (168, 44%; 167, 30%). 
 









26 (K-76 COONa)   0.68 > 0.68 
159 H CHO > 1.56 > 1.56 
162 H CO2H > 1.44 > 1.44 
160 Me CHO 1.10 > 1.46 
161 Ph CHO > 1.12 > 1.12 
163 Me CO2H > 1.35 > 1.35 
164 Ph CO2H > 1.06 > 1.06 
167 Ph Tetrazole-5-yl 0.20 0.65 
168 Me Tetrazole-5-yl 0.25 > 1.22 
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The target compounds were analyzed for their ability to inhibit the classical pathway 
activation of human Complement (Table 3);113 their lytic activity was also tested, by incubation 
with sensitized sheep erythrocytes in the absence of Complement. None of the CD-ring 
analogues exhibited lytic activity, except phenyl ether 167. 
The acids and the aldehydes were less potent than the natural product; however, potency was 
significantly improved by the replacing the carboxylic acid functionality with a tetrazole ring. 
These results suggested that the presence of an ionizable functional group at position 6 is 
relevant for Complement inhibition. 
 
6.2. Synthesis and evaluation of BCD-ring analogues 
Bradbury and Sindelar synthesized a series of BCD-ring analogues of K-76114 following a 
general strategy reminiscent to that employed by Kaufman and Sindelar for the preparation of 
grisan, using successive regioselective heteroatom-facilitated aromatic lithiation reactions.115 
This approach allowed the introduction of different substituents at position-7 from a single 
intermediate, and the regioselective functionalization of the aromatic moiety to give 6,7-
disubstituted derivatives. 
As shown in Scheme 15, cyclohexanone (131) was subjected to the addition of cyanide 
anion, followed by dehydration of the intermediate cyanohydrin and subsequent Pinner-type 
acid-catalyzed ethanolysis, furnishing unsaturated ester 169. In turn, this was reduced to the 
corresponding alcohol with LiAlH4 and further converted to the required allylic bromide 170 
with PBr3 in pyridine in 45% overall yield. On the other side, the aromatic component 172 was 
prepared in high yield from the commercially available phenol 171. 
Coupling of 170 and 172 was performed in 91% yield by heteroatom directed ortho-
metallation of the latter with the nBuLI-TMEDA complex, followed by conversion of the 
organolithium species to the corresponding cuprate with CuI at low temperature. A second 
heteroatom facilitated ortho-lithiation followed by quenching the intermediate organolithium 
species with different electrophiles provided compounds 174a-d in 61-92% yield. In turn, these 
were submitted to acid hydrolysis to yield phenols 175, setting the stage for the cyclization step. 
Interestingly, during the preparation of 174d formation of compound 178 could be observed in 
up to 40% yield, when the reaction was performed at 0ºC. This resulted from nitrogen-assisted 
displacement of the methoxy group from the neighbour MOM ether. On the other hand, 174c 
was highly sensitive to acid media and did not withstand MOM removal conditions. 
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173 174a, R1= CO2H, R2= H
174b, R1= CHO, R2= H
174c, R1= CH2OH, R2= MOM





























Scheme 15. Reagents and conditions: a) 1. NaCN, NaHSO3, H2O, 0ºC, 4h; 2. POCl3, Pyridine, 
PhH, reflux, 30 min; 3. H2SO4, EtOH, reflux, 72h (50% overall); b) 1. LiAlH4, Et2O, reflux, 30 
min; 2. PBr3, hexanes, -12ºC rt, 24h (90%); c) MOMCl, K2CO3, 18-Crown-6, MeCN, rt, 10h 
(96%); d) 1. nBuLi, TMEDA, THF, 0ºC, 2h; 2. CuI, -40ºC, 90 min; -78ºC rt, 16h (91%); e) 1. 
nBuLi, TMEDA, Hexane, 0ºC rt, 3h; 2. E+, -78ºC; 3. HCl, 2-PrOH, rt, 16h [E+= CO2, 174a, 
66%; E+= DMF, 174b, 92%; E+= (CH2O)n, 174c, 64%; E+= MeNCO, 174d, 61%]; f) Amberlyst-
15, PhH, rt, 24h (175a, 85%; 175b, 83%; 175d, 94%); g) tBuSLi, HMPA, 0ºC, 12h (176a, 55%; 
176b, 93%; 176d, 94%); h) Ag2O, NaOH, H2O, 80ºC, 72h (50%); i) nBuLi, 
Me2NCH2CH2NHMe, THF, DMF, -20ºC, 24h (34%); (j) AgOH, AgNO3, KOH, EtOH-H2O, rt, 
2h (91%); k) AgOH, Ag2O, KOH, THF-H2O, rt, 2h (7-14%). 
 
Submission of the cyclohexenyl phenols 175a,b to Amberlyst-15 mediated cyclization 
afforded the corresponding tricyclic methyl ether derivatives 176a,b, which were cleaved to the 
corresponding free phenols 177a,b with lithium tert-butyl mercaptide.116  
Aldehyde 175b was further functionalized through a third ortho-directed metallation under 
the conditions initially developed by Comins and Brown, where N,N’,N”-
trimethylethylenediamine was used as an amine component for the in situ formation of α-amino 
alkoxides, which served the purposes of protecting the formyl group and directing lithiation.117 
The reaction furnished a moderate yield of dialdehyde 177a; in turn, this was oxidized to the 
monocarboxylic acid 177c or to the diacid 177b with silver(I) reagents under basic conditions.  
In an analogous fashion, C6 substituted analogues were prepared, as shown in Scheme 16, which 
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were further functionalized to afford 6,7-disubstituted BCD-ring analogues of K-76.118 
Benzyl alcohol 179, easily available in 95% yield from the corresponding ester, by LiAlH4 
reduction, was partially oxidized with buffered PCC and acetalized to afford intermediate 180. 
This was coupled with 1-bromomethyl cyclohexene as before, employing organocopper 
chemistry, to obtain 71% of aldehyde 181 after acid hydrolysis. Lithium tert-butyl mercaptide-
assisted cleavage of one of the methyl groups furnished phenol 182, which was uneventfully 
transformed into tricyclic aldehyde 183 by reaction with Amberlyst-15. Final demethylation 
yielded 87% of free phenol 184. When the aldehyde 182 was subjected to a silver oxide-
mediated oxidation, 94% of the benzoic acid derivative 185 was isolated; this was easily cyclized 
with Amberlyst-15, affording 94% of 187. The related 186 was prepared in 91% yield by Ag2O-


































188 189, R= Me
190, R= Hc
191, R1,R2= CH2OC(O)












Scheme 16. Reagents and conditions: a) 1. PCC, NaOAc, CH2Cl2, rt, 16h (87%); 2. TsOH, 
CaCl2, MeOH, rt, 3h (84%); b) 1. nBuLi, TMEDA, THF, rt, 3h; 2. CuI, -45ºC, 1.5h; 3. 1-
bromomethylcyclohexene (170), -70ºC rt, 24h; 4. Et2O, 5% HCl, 16h (180, 71%; 188, 77%); c) 
tBuSLi, HMPA, rt, 48h (182, 93%; 184, 87%; 190, 74%); d) Amberlyst-15, PhH or CH2Cl2, rt, 
overnight (183, 96%; 186, 91%; 191, 95%); e) Ag2O, NaOH, H2O, rt, 16h (181 185, 94%; 
184 187, 96%); f) nBuLi, TMEDA, CO2, hexanes, -78ºC, 1h (66%) g) KMnO4, TBAF, NaOH, 
THF-H2O (53%). 
 
On the other side, coupling the benzylic alcohol 179 with 1-bromomethylcyclohexene (170) 
yielded symmetric intermediate 188, which was carboxylated with carbon dioxide to phthalide 
189 in 66% yield.119 Selective demethylation of the methyl ether located ortho to the carbonyl 
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moiety (190, 74%) followed by Amberlyst-15 mediated cyclization gave 95% of tetracyclic 
lactone 191, the oxidation of which with the KMnO4-TBAF reagent mixture120 furnished acid-
aldehyde 192 in moderate yield. 
The synthetic analogues were tested for their ability to inhibit Complement activation in the 
classical and alternative pathways. Although the natural product is a free phenol, methyl ether 
derivatives carrying a C6 carboxyl group (177b, 177c, 185 and 186) displayed activities (IC50 
values ranged from 0.16 to 0.82 mM) comparable to that of K-76 COOH (28, IC50= 0.57 mM) in 
the inhibition of total hemolysis. On the other hand, phenol 187 exhibited slightly reduced ability 
to inhibit total hemolysis (IC50= 1.45 mM). A similar effect on Complement activity was 
observed among the ACD-ring analogues (see below). However, the most potent analogue 
(177c) was that retaining the carbonyl substitution pattern of the natural product (however, 
carrying an O-methyl ether).  
The ability of the analogues to inhibit the lysis of rabbit red blood cells by the alternative 
Complement pathway121 was also assessed (Table 4). Since higher concentrations of human 
serum are required to achieve proper lysis of the rabbit erythrocytes by the alternative pathway 
than those needed to lyse antibody-sensitized sheep red blood cells, IC50 values by the classical 
and alternative pathways are not comparable. 
 






174a, 185 175a, 176a, 177b,c,
186, 187, 192  




28 CO2H CHO H 0.57 0.33 
174a H CO2H Me 2.1  
175a H CO2H Me 1.3 2.2 
176a H CO2H H 3.0  
177b CO2H CO2H Me 0.8 1.2 
177c CO2H CHO Me 0.16 0.73 
185 CO2H H Me 0.82 3.5 
186 CO2H H Me 0.53 2.2 
187 CO2H H H 1.5 3.8 
192 CHO CO2H Me 1.7 1.9 
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 However, analogue 177c inhibited hemolysis by the alternative pathway with IC50= 0.73 
mM, comparable to the activity displayed by the natural product (28, IC50= 0.33 mM). The other 
analogues were slightly less active, with IC50 values ranging between 1.2 and 3.8 mM. 
 
6.3. Synthesis and evaluation of ACD-ring analogues 
The group of Sindelar prepared C6- and C7-substituted ACD ring analogues of K-76 employing 
both enantiomers of limonene122 and (R)-carvone as starting materials for building the A-ring 
moiety. The enantiomers of limonene were individually submitted to metallation at the propenyl 
side chain123 and the resulting species were subjected to treatment with oxygen, leading to 
hydroperoxydic intermediates, which were reduced in situ to the corresponding allyl alcohols 
208. In turn, these were converted into the required allylic chlorides 193 by reaction with the 
PPh3/CCl4 reagent.124  
For the preparation of the C7-substituted analogues, allylic chloride 193 was coupled in 93% 
yield to resorcinol derivative 194, synthesized in good yields from 3-methoxyphenol (171), 
employing an heteroatom-facilitated ortho-directed lithiation (Scheme 17), followed by 
transformation of the lithium species into organocopper intermediates.  
A second heteroatom directed ortho lithiation performed on 194 coupled to reaction with 
DMF, CO2 and ethyl carbonate furnished carbonyl derivatives 195-197 in 60-64% yield. Because 
the direct carboxylation of 194 with CO2 gave no clean products, ester 197 was prepared.  
In turn, these intermediates were selectively deprotected under acid conditions (198-199a) 
and 199a was converted into 199 (92%) by basic hydrolysis. Next, the resulting free phenols 
were subjected to Amberlyst-15 cyclization, affording dihydrobenzofuran derivatives 200-202 in 
73-81% yield, as diastereomeric mixtures at the quaternary carbon level. Final cleavage of their 
methyl ether moiety with tBuSLi in HMPA furnished phenols 203-205 in 95-97% yield. On the 
other hand, ester 205 was also transformed into acid 204 (85%) by NaOH-mediated hydrolysis. 
The ability of the synthesized analogues to inhibit Complement activation and production of 
anaphylatoxins C3a and C5a was assayed. The enantiomers of aldehydes 200 and 203 exhibited 
poor aqueous solubility, which precluded testing. However, both enantiomers of acid 201 were 
active (IC50= 8 mM and 6 mM), being the S-enantiomer slightly more potent and comparable to 
K-76 COONa (IC50= 3 mM), while the corresponding free phenols 204 proved to be essentially 
inactive at the C5a and C3a levels.  
The capacity of the compounds to inhibit Complement-mediated erythrocyte lysis 
(hemolysis) was also assessed.125 Both enantiomers of the acids 201 and 204 demonstrated to be 
active (IC50= R-201, 0.750 mM; S-201, 0.24 mM; R-204, 2.15 mM; S-204, 2.41 mM) in the 
same order of magnitude than K-76 COONa (0.57 mM), albeit the free phenols were less potent. 
These authors also evaluated the capacity of the acids to inhibit the mitogen-stimulated 
proliferation of lymphocytes. When the immunosuppressant OKT-3 and phytohemagglutinine 
were employed as mitogens, the IC50 values of the synthetic inhibitors were slightly higher than 
those of K-76 COONa. 
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Scheme 17. Reagents and conditions: a) MOMCl, NaH, DMF, rt, overnight (89%); b) 1. nBuLi, 
TMEDA, hexane, 0ºC; 2. CuI, -45ºC, 1h; 3. 193 -78ºC rt, 3h (93%); c) nBuLi, TMEDA, Et2O, 
DMF (64%); d) nBuLi, TMEDA, Et2O, CO2; e) nBuLi, TMEDA, Et2O, CO3Et2 (60%); f) 3N 
HCl, 2-PrOH (198, 92%; 199, 40% from 194; 199a, 88%); g) Amberlyst-15, CH2Cl2 (200, 73%; 
201, 77%; 202, 81%); h) tBuSLi, HMPA (203, 95%; 204, 97%; 205, 97%); i) 30% NaOH, EtOH, 
reflux, overnight (85%); j) 1. nBuLi, TMEDA, rt, 24h; 2. O2, -35ºC; k) Na2SO3; l) PPh3, CCl4, 
CH2Cl2, reflux (91% overall); m) 40% KOH, overnight, rt (92%). 
 
More functionalized C7 substituted analogues were obtained from R-carvone (209).126 These 
were designed with the hope to overcome the problem of diastereomer formation among the 
ACD-ring analogues derived from the limonene enantiomers. After studying the steric and 
electronic factors that contribute to the cyclization and analysis of molecular models of the 
cyclising phenol, it was concluded that provision of interactions between the A and D rings could 
afford a rigid intermediate and induce a preferred conformation that would allow a preferential 
side attack of C8 by the phenolic hydroxyl.  
In order to provide such interactions, functionalization of the endocyclic double bond of the 
alicyclic moiety was proposed with the expectation that regio- and stereospecific hydroxylation 
would not only provide the proper hydrogen bonding interactions to induce the cyclization, but 
also generate analogues carrying a cis-diol functionalization similar to that found in the natural 
product. Following the procedures of Itoh and Royals, R-carvone (209) was reduced to the 
corresponding allylic alcohol (210), which was submitted to a TBHP-mediated epoxidation (211) 
directed and catalyzed by VO(Acac)2 (Scheme 18). 
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Reductive opening of the epoxide form the less hindered side afforded cis-diol 212, which 
was then protected as the acetonide (213) and allylically halogenated with the calcium 
hypochlorite-dry ice reagent to furnish 214.127 
Metallation of 172 initiated the coupling with 214 to afford 68% of 215. An ortho-directed 
metallation of 215, followed by treatment of the organometallic intermediates with ethyl formate 
and ethyl carbonate and mild acid hydrolysis provided 46% of 216 and 53% of 218, respectively.  
Acid 217 was obtained by saponification of the corresponding ester in 96% yield. Acid 
hydrolysis of the products caused removal of the MOM ether moiety, leaving phenolic 


































222, R1= H, R2= Me
223, R1= OEt, R2= Me
224, R1= OEt, R2= H
225, R1= OH, R2= Me
226, R1= OH, R2= H
















Scheme 18. Reagents and conditions: a) LiAIH4, THF; b) tBuOOH, VO(Acac)2; c) LiAlH4, 
THF, reflux; d) Me2C(OMe)2, TsOH; e) Ca(ClO)2, CO2, CCl4; f) nBuLi, TMEDA, CuI, 172 
(88%); g) nBuLi, TMEDA, HCO2Et (R= H, 46%), CO3Et2 (R= OEt, 53%); h) 30% NaOH, 
EtOH-H2O, reflux (96%); i) SiO2, 1% AcOH, EtOAc (79-96%); j) Amberlyst-15, CH2Cl2 (91-
92%); k) tBuSLi, HMPA.  
 
This was performed with Amberlyst-15, furnishing 222, 223 and 225 in 91-92% yield. 
Among these compounds, it was expected that interaction between the secondary alcohol and the 
carbonyl moiety would lead preferentially or exclusively to one diastereomer. Finally, cleavage 
of the methyl ether with tBuSLi in HMPA yielded phenolic analogues 224 and 226. 
Evaluation of representative analogues was performed, since compounds 219 and 221-224 
exhibited poor aqueous solubility. Therefore, analysis of 220 and 225 was carried out for 
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inhibition of the classical and alternative121 Complement pathways, with the results consigned in 
Table 5. These results suggested that the cis-diol moiety may not be a structural requirement for 
Complement inhibition. 
 













Compound Nº Classical pathway IC50 (mM) Alternate pathway IC50 (mM) 
28, K-76 COONa 0.57 0.85 
220 24% at 2.0 mM - 
225 1.60 2.55 
 
Next, fluoro-desilylation of the silyl ether was followed by PCC-mediated partial oxidation 
of the intermediate benzylic alcohol furnished aldehyde (228), which was deprotected with 3N 
HCl in 2-propanol, yielding a mixture of mono- and bis-deprotected aldehydes 229 and 230.  
Upon cyclization with Amberlyst-15, both aldehydes afforded phenolic aldehyde 232; 
however, the MOM-ether 235 was not isolated. The phenol moiety was protected as methyl 
(233) and phenyl (234) ethers in 95% and 75% yield, respectively, and the three tricyclic 
aldehydes were subjected to a silver(I)-mediated oxidation to the corresponding carboxylic acids 
(235-237) in good yields. Finally, 236 was dihydroxylated to give 68% of diol 238. 
The synthetic analogues were tested for their ability to inhibit activation of the Complement 
system and for their intrinsic lytic activity (Table 6). The results indicated that compounds 232 
and 235 display in vitro inhibition of classical human Complement-mediated hemolysis in the 
same range of concentrations as the natural product. This suggests that the presence of a formyl 
group in the D-ring may not be an essential requirement for Complement inhibition. In addition, 
among the carboxylic acids the analogues substituted at C6 were more potent than those 
functionalized at C7. 
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227, R1= CH2OTBDMS, R2=R3= MOM
228, R1= CHO, R2=R3= MOM
229, R1= CHO, R2= H, R3= MOM

















Scheme 19. Reagents and conditions: a) nBuLi, TMEDA, CuI, S-193 (82%); b) 1. TBAF, THF; 
2. PCC, CH2C12 (90%, overall); c) 3N HCl, 2-PrOH, rt, 8h (229, 21%; 230, 52%); d) Amberlyst-
15, CH2Cl2, rt; e) CH3I, Ag2O, CHCl3 (95%); f) Ph3Bi(OAc)2, Cuº, CH2C12 (75%); g) AgNO3, 
KOH, EtOH, H2O (235, 63%); h) OsO4, Me3NO.2H2O, tBuOH (68%). 
 

























233, R1= H, R2= Me
234, R1= H, R2= Ph
235, R1= OH, R2= H
236, R1= OH, R2= Me
237, R1= OH, R2= Ph
4'
225, R1= H, R2= CO2H














26 0.68 > 0.68  233 > 1.05 > 1.05 
R-170 0.68 -  234 > 0.86 > 0.86 
S-170 0.38 -  235 0.73 > 1.04 
R-204 2.10 -  236 > 1.00 0.66 
S-204 2.10 -  237 > 0.82 < 0.20 
225 1.60 -  238 > 0.89 > 0.89 
232 0.52 < 0.28  - - - 
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In light of these results, the phenolic hydroxyl also seems to play an important role especially 
when the carboxyl group is at C6. The phenoxy derivatives 234 and 237 were inactive, while 
poor activity was observed in case of the methoxy acid derivative 236. Lipophilicity changes in 
the A- (diols 226 and 238) and/or D-rings affected the intrinsic lytic activity of the analogues. 
In view of the compared better potency of the analogues prepared with the S-enantiomer of 
limonene, the C6 analogues were prepared according to a similar strategy,128 as depicted in 
Scheme 19, employing S-193. Therefore, the bis-MOM derivative 155 was submitted to an ortho 
lithiation and coupled with the S-enantiomer of chloride 193, employing organocopper chemistry 
(227). 
 
6.4. Semi-synthetic filifolinol derivatives as K-76 COOH analogues. Biological 
evaluation 
More recently, a new series of K-76 COOH analogues was elaborated by the group of 
Kaufman,129 inspired in the similarity between 28 and filifolinol (31), an abundant naturally-
occurring spiro-benzofuran cyclohexane.  
Based on a semi-synthetic approach, systematic studies were conducted in order to identify 
parts of the basic structure which may lead to more potent Complement inhibitors, as well as to 
identify structural features responsible of intrinsic hemolytic activity. With this aim, in an initial 
study, a small collection of compounds was prepared, through modification of the substituents on 
the aromatic ring (Scheme 20). 
Mild hydrolysis of filifolinol (31) with LiOH in THF-H2O gave 80% of acid 240. The acid-
nitrile 244 was prepared by conversion of filifolinol into acetate 239 in 92% yield and 
submission of the latter to an electrophilic bromination, which yielded 91% of bromide 241a. 
This key intermediate was transformed into the corresponding cyanide 243 in 55% yield, with 
Zn(CN)2 in DMF under microwave irradiation and Pd(PPh3)4 catalysis; this alternative proved to 
be superior than conventional thermal heating. Basic hydrolysis of 243 (LiOH, THF-H2O) 
furnished 72% of the desired acid-nitrile 244. 
The aryl bromide intermediate 241 was hydrolyzed, furnishing 242, which was also obtained 
by direct bromination of 239 with Br2 in glacial AcOH; however, yields were substantially lower 
(< 20%). On the other hand, for the synthesis of phenol 248, filifolinol was reduced to benzylic 
alcohol 245 with LiAlH4 and this was selectively oxidized BaMnO4 to the corresponding 
aldehyde 246. In turn, the aldehyde was subjected to a Baeyer-Villiger oxidation with m-CPBA, 
affording formate 247 in 85% yield; final hydrolysis of the formate (10% NaHCO3, THF-H2O) 
afforded 80% of 248. 
Transesterification of 247 with the Ac2O-pyridine reagent furnished 75% of the diacetate 
249, which upon irradiation with UV-light at 254 nm suffered a photo-Fries rearrangement, 
providing a 2:1 mixture of ortho-hydroxy acetophenones 250 and 251 in 63% combined yield. 
Quantitative hydrolysis of the latter (NaOH, THF-H2O) to 252 and 253, respectively, gave the 
required final products. The Complement inhibitory activity of this series of semi-synthetic 
analogues was tested and compared with literature data for K-76 COOH and partial analogues 
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250, R= H, R1=R2= Ac
251, R=R2= Ac, R1= H
252, R=R2= H, R1= Ac




Scheme 20. Reagents and conditions: a) LiOH, THF-H2O, rt, 2h (80%); b) Ac2O, Et3N, CH2Cl2, 
rt, overnight (92%); c) Br2, AcOH, 0ºC→rt, overnight (239→241a, 91%); d) LiOH, THF-H2O, rt 
(82%); e) Zn(CN)2, Pd(PPh3)4 (5 mol%), DMF, MW (400 W), 55 min (55%); f) LiOH, THF-
H2O, rt, 2h (72%); g) LiAlH4, THF, rt, 3h (95%); h) BaMnO4, CH2Cl2, reflux, 48h (91%); i) m-
CPBA, CHCl3, 55ºC, 1.5h (85%); j) 10% NaHCO3, THF-H2O, rt, 4h (80%); k) Ac2O, Pyridine, 
DMAP, CH2Cl2, rt, overnight (75%); l) Hexane, hν (254 nm), rt, 2h (63%); m) NaOH, THF-
H2O, 2h, rt (100%). 
 
From analysis of this first approach, it was concluded that the novel and easily available 
acids 240, 242 and 244 as well as phenol 248 and acetophenone 253 displayed comparable 
activity to that of K76-COOH analogues, such as 186, being their potencies of the same order of 
magnitude of 28. On the other hand, acetophenone 252 was active but exhibited solubility 
problems. Quite interestingly, functionalization of C7 (242 and 244 vs. 240) decreased IC50 
among the acids, while surprisingly phenol 248 displayed remarkable potency, exhibiting an IC50 
value slightly lower than that of K76-COOH.  
Previous findings had shown that a phenolic hydroxyl group was important for the activity of 
ACD-ring acid analogues of K-76 (225, 226)104, 128 and that methyl ethers were more active than 
their corresponding free phenols among the BCD-ring analogues (175, 177c, 186).104, 112, 118 In 
the present case, however, the acids 240, 242 and 244 were active despite the absence of methyl 
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ether or free phenol moieties. 
 















248, R1= R2= H
252, R1= Ac, R2= H





175a, R1= H, R2= CO2H 
177c, R1= CO2H, R2= CHO








Entry Nº Compound Nº IC50 (mM)a IC50 (mg/mL)a 
1 240 2.00 0.58 
2 242 0.95 0.35 
3 244 1.32 0.42 
4 248 0.46 0.26 
5 252 -b -b 
6 253 1.07 0.32 
7126 28, K-76 COOH 0.57 0.24 
8118 175a 1.30 0.34 
9118 177c 0.16 0.044 
10118 186 0.82 0.21 
11126 225 1.60 0.52 
a Concentration required to inhibit Complement induced hemolysis by 50% compared to the 
control (without test compound). Values reported were obtained by interpolation in the 
corresponding concentration/inhibition (%) plots. Samples were run in duplicate. Results are 
within the ± 5% error. b At a concentration of 253 µg/mL, acetophenone 252 produced 17 ± 5% 
inhibition. Poor solubility of the compound precluded testing more concentrated solutions. 
 
In addition, the compounds retained activity regardless of the fact that the carboxyl group 
was attached to the aromatic ring para to the benzofuran oxygen instead of meta as in 28. Other 
interesting findings from this series of compounds were that, as observed in the cases of 25/28b 
and their lower analogues,126 the carboxylic acid moiety conveniently imparted better solubility 
to the compounds. However, results of 248 and 253 also suggested that a carboxyl group may not 
be essential for the analogues to display biological activity. 
In a second approach, and based on these previous results, Larghi and co-workers130 
systematically explored the effects of modifying C3’. In order to prepare the proposed analogues 
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with alcohol or diol-bearing chains, the secondary alcohol of the natural product was submitted 
to an O-allylation (Scheme 21), which gave equal amounts of the expected compound 254 and 
























































Scheme 21. Reagents and conditions: a) NaH, BrCH2CH=CH2, THF-DMF, rt, 25h (89% 
254/255≈ 1); b) OsO4 (cat.), K3Fe(CN)6, K2CO3, tBuOH-H2O, rt, 21h (78%); c) NaOH, Dioxane, 
60ºC (240, 85%; 255, 59%; 260, 99%); d) 1. KIO4, Acetone, rt, 2.5h, 2. NaBH4, 2-PrOH, rt, 20h 
(82%); e) H2 (1 atm.), 10% Pd/C, EtOH, rt, 5h (98%); f) 1. SOCl2, DMF (cat.), CHCl3, reflux, 
1.1 h (74%); 2. H2 (1 atm.), 10% Pd/C, MeOH, rt, 2.45h (99%). 
 
Allyl ether 254 was subjected to an osmium tetraoxide-catalyzed dihydroxylation, furnishing 
diols 256 as a diastereomeric mixture. The latter was further oxidatively cleavaged in 78% yield 
with the OsO4-KIO4 reagent system,131 yielding 82% of the mono-protected ethylene-glycol 
derivative 257 after a NaBH4 reductive step.  
For the sake of comparison, 255 was catalytically hydrogenated (Pd/C, EtOH) to acid 258 
(98% yield) and 31 was deoxygenated in 74% overall yield by means of a three-step process 
involving a chlorodehydroxylation followed by in situ hydrogen chloride elimination and final 
catalytic hydrogenation to 259. For testing purposes, the corresponding acids 240, 255, 256, 257 
and 258 were obtained by basic hydrolysis.  
Another group of derivatives carrying C3’ modifications was prepared by amination and 
Grignard addition reactions (Scheme 22). To that end, filifolinol was first oxidized to filifolinone 
(261)69b in 90-92% yield and this was reacted with allyl Grignard, furnishing 62% of tertiary 
alcohol 263 as a sole diastereomer. 
Next, osmium-mediated catalytic dihydroxylation of 263 gave 87% of diols 264. On the 
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other hand, NaBH4-mediated reduction of filifolinone provided 60% of 3’-epifilifolinol (266), 
while base-catalyzed transesterification of 261 to 262 followed by a reductive amination of the 
ketone132 with allylamine furnished amines 268 as a separable mixture of diastereomers in 74% 
overall yield. Upon catalytic hydrogenation, 3'R-268 and 3'S-268 conveniently provided the free 
N-npropylamino acids 3'R-269 and 3'S-269, respectively. The congener acids 260, 265a,b and 











































3'R-268 R=        H




















3'R-269 R=        H
3'S-269 R=        H
 
Scheme 22. Reagents and conditions: a) 1. DMSO, TFAA, CH2Cl2, -60ºC, 2. TEA, 0ºC→rt, 
35min. (90%) or PCC/Al2O3, CH2Cl2, rt, 23h (95%); b) BrMgCH2CH=CH2, Et2O, 0ºC, 2.5h 
(62%); c) OsO4 (cat.), K3Fe(CN)6, K2CO3, tBuOH-H2O, rt, 23h (87%, α/β ≈ 1.5); d) NaOH, 
Dioxane, 60ºC, 22h (92%); e) NaBH4, EtOH, 0ºC, 3h (60%); f) BnOH, NaH (cat.), PhMe, 70ºC, 
2.5h (65%); g) 1. H2NCH2CH=CH2, AcOH, MgSO4, 4Å MS, EtOH, reflux, 19h; 2. NaCNBH3, 
EtOH, rt, 22h (74%, 3’R-268/3’S-268≈ 3:1); h) H2 (1 atm.), 10% Pd/C, MeOH, rt, 4h (3’R-268, 
90%; 3’S-268, 90%); i) H2 (1 atm.), 10% Pd/C, MeOH, rt, 2.1h (83%). 
 
The activity of the synthetic analogues as inhibitors of Complement classical pathway 
activation was tested and compared with literature data (Table 8). The introduction of diversity at 
the C3’ position generated derivatives showing broadly different inhibitory profiles. From the 
results of this structure-activity study it was deduced that introduction of a three-carbon chain at 
the C3’ carbinol moiety (255, 258) did not improve the Complement inhibitory activity; 
moreover, introduction of alcohol or diol functionalities in the side chain to mimic the diol 
moiety of K76-COOH (256, 257)133 surprisingly lead to less active compounds, perhaps because 
they were laid in a different conformational space. In fact, the activity of the parent compound 
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was restored in 265a,b, where the hydroxyl groups exhibit good superimposition with the diol 
moiety of the natural product. On the other hand, removal of the C3’ hydroxyl group furnished 
analogue 260, which behave as a hemolytic agent.  
 In addition, it was observed that the stereochemistry of the C3’ functionality is relevant to 
activity, being acid 240 near 24 times more active than acid 267, its C3’ epimer carrying the 3’S 
configuration. The same trend was observed among the nitrogen-containing analogues 269, 
where the 3’R isomer was approximately 13 times more potent than its 3S congener. 
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240, R=        OH
260, R= H
267, R=        OH
 
Complement inhibitiona Complement Inhibitiona Compd. Nº 
IC50, mM IC50, mg/mL 
Compd. Nº 
IC50, mM IC50, mg/mL 
240 0.52 0.15 265a 0.48 0.18 
255 3.08 1.01 265b 3.29 1.20 
256 4.72 1.72 267 12.1 3.52 
257 4.40 1.47 3'R-269 0.21 0.07 
258 0.55 0.19 3'S-269 2.75 0.91 
260 Hemolytic 28, K-76 COOH 0.57 0.24 
S-204122 2.15  S-170118 0.38  





Complement activation has several benefits, including provision of resistance towards infectious 
agents, processing naturally generated immune complexes and developing an optimal humoral 
immune response. However, under certain circumstances and conditions, the Complement 
system may become activated and, as part of its complex functions, yield undesirable results, 
including injury, deepening or worsening of a disease.  
The artificial manipulation of the balance between Complement activation and inhibition 
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represents a very interesting therapeutic opportunity to ameliorate the negative effects of 
abnormal Complement activation and lessen pathological events in disease states and 
interventional conditions. 
The desirable properties of a broadly applicable anticomplement therapeutic agent, useful in 
acute and chronic conditions include inexpensiveness, high specificity and very long plasma 
half-life. It should be active orally and block pathological activation of Complement while 
causing minimal disruption of the systemic Complement function. None of the currently 
available agents fit all these characteristics, but this unmet need has driven research over the last 
three decades and substantial progress has been made. However, there are no currently available 
low molecular weight oral therapies for temporally targeting undesirable or abnormal 
Complement system activation without negatively affecting the beneficial functions of 
Complement or interfering with other complex cascades that Complement is linked to.  
K76-COOH, the partial oxidation derivative of the naturally-occurring K-76, demonstrated to 
be influential under different conditions involving the Complement system and the immune 
system, and the source of inspiration for the development of new molecular entities capable of 
inhibiting the Complement system. 
Although there is much room left to improve, interesting progress has been observed. The 
development of more effective and specific Complement inhibitors will provide potential 
therapeutic agents for diseases in which this pathway is determined to be critical, and powerful 
new tools with which to dissect the role of Complement in various diseases and at different 
points during the evolution of tissue injury. Moreover, it can be anticipated that, analogous to the 
utility of pharmaceutically useful inhibitors of the coagulation cascade, Complement inhibitors 
will find an important niche in the pharmacologic arsenal to reduce undesirable inflammatory 
reactions. It is not unlikely to expect that in another two decades or so humankind will have 
agents that meet most of the desirable properties of an ideal oral Complement inhibitor, enabling 
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